Featured Jobs
Defined Benefit Calculation Specialist/Actuary The Angell Pension Group, Inc.
|
Trucker Huss, A Professional Corporation
|
United 401(k) Plans, Inc.
|
Prime Pensions, Inc.
|
Nova 401(k) Associates
|
Nicholas Pension Consultants
|
Central Pension Fund of the IUOE
|
Bates & Company
|
DPS Retirement Plan Consultant EPIC Retirement Plan Services
|
Benefit Associates, Inc.
|
Retirement Plan Legal Specialist Pentegra
|
Carpenter Morse Group
|
Retirement, LLC
|
Retirement Plan Relationship Manager ERISA Services, Inc.
|
Compass Retirement Consulting Group, Inc.
|
Central Pension Fund of the IUOE
|
Free Newsletters
“BenefitsLink continues to be the most valuable resource we have at the firm.”
-- An attorney subscriber
 |    |
<< Previous news item | Next news item >>
| How an $84,000 Drug Got Its Price: 'Let's Hold Our Position ... Whatever the Headlines' The Washington Post; subscription may be required  Dec. 2, 2015 "Gilead gained federal approval for its drug Sovaldi in late 2013 and ultimately settled on the price of $84,000 for a 12-week course of treatment. To the company, that price seemed to deliver the right balance: value to shareholders while also not so high that insurers would 'hinder patient access to uncomfortable levels' ... But they also got more than they bargained for: an outpouring of outrage from the public, a backlash from government and private payers, and political scrutiny." |
| Please click here to report this link if it is broken (for example, if you see a "404 File Not Found" error message after you click on the link above). |
| An important word about authorship: BenefitsLink® is providing a hypertext link to the item shown above, but is not the author of the item (unless otherwise specified). |
